Practices

Capital Markets

Captial Markets: Recent Follow-on Offerings

Since 2009, we have been involved in 450+ public offerings including some of the nation's most notable securities transactions. Following are some recent representative offerings.

Completed Follow-on Offerings

  • Underwriters in Reata Pharmaceuticals $115.9 million Follow-On (July 2017)
  • Regulus Therapeutics $46.0 million Follow-On (July 2017)
  • Apollo Endosurgery $31.3 million Follow-On (July 2017)
  • Inovio Pharmaceuticals $75.0 million Follow-On (July 2017)
  • CymaBay Therapeutics $97.2 million Follow-On (July 2017)
  • Alder Biopharmaceuticals $172.5 million Follow-On (July 2017)
  • Arena Pharmaceuticals $150.0 million Follow-On (July 2017)
  • Underwriters in Egalet Corporation $30.0 million Follow-On (July 2017)
  • Minerva Neurosciences $41.8 million Follow-On (June 2017)
  • AveXis $287.5 million Follow-On (June 2017)
  • Underwriters in Pacific Biosciences of California $47.8 million Follow-On (June 2017)
  • Underwriters in Savara $42.9 million Follow-On (June 2017)
  • Senseonics $41.0 million Follow-On (May 2017)
  • GlycoMimetics $92.6 million Follow-On (May 2017)
  • Syndax Pharmaceuticals $49.7 million Follow-On (May 2017)
  • Underwriters in MINDBODY $141.4 million Follow-On (May 2017)
  • ZioPharm Oncology in its $50.0 million Follow-On (May 2017)
  • Underwriters in Arbor Realty Trust $77.9 million Follow-On (May 2017)
  • Underwriters in Accelerate Diagnostics $79.4 million Follow-On (May 2017)
  • Cytokinetics in its $75.0 million Follow-On (May 2017)
  • Underwriters in Ignyta $88.4 million Follow-On (May 2017)
  • Underwriters in AGNC Investment Corp. $507.2 million Follow-On (May 2017)
  • Underwriters in TransEnterix $24.9 million Follow-On (April 2017)
  • Underwriters in Karyopharm Therapeutics $40.0 million Follow-On (April 2017)
  • Underwriters in Audentes Therapeutics $86.3 million Follow-On (April 2017)
  • Arena Pharmaceuticals $79.4 million Follow-On (April 2017)
  • Underwriters in Wave Life Sciences $100.0 million Follow-On (April 2017)
  • Axovant $143.7 million Follow-On (April 2017)
  • FibroGen $120.0 million Follow-On (April 2017)
  • Everbridge $73.8 million Follow-On (April 2017)
  • Cara Therapeutics $92.1 million Follow-On (March 2017)
  • Underwriters in CytoSorbents $9.99 million Follow-On (March 2017)
  • Biocept $9.3 million Follow-On (March 2017)
  • Underwriters in Vital Therapies, Inc. $40.3 million Follow-On (March 2017)
  • Underwriters in Heat Biologics Inc.$4.0 million Follow-On (March 2017)
  • Bellicum Pharmaceuticals, Inc. in its $69.0 million Follow-On (March 2017)
  • Calithera Biosciences, Inc. in its $80.5 million Follow-On (March 2017)
  • Underwriters in Intrepid Potash, Inc. $60.4 million Follow-On (March 2017)
  • Underwriters in Anthera Pharmaceuticals, Inc. $15.0 million Follow-On (March 2017)
  • Aurinia Pharmaceuticals Inc. in its $173.1 million Follow-On (March 2017)
  • Underwriters in Ooma, Inc. $29.1 million Follow-On (March 2017)
  • Kite Pharma, Inc. in its $409.7 million Follow-On (March 2017)
  • Underwriters in Dermira, Inc. $193.8 million Follow-On (March 2017)
  • Underwriters in Global Blood Therapeutics $143.8 million Follow-On (February 2017)
  • Helius Medical Technologies in its $9.5 million Follow-On (February 2017)
  • Underwriters in Sierra Oncology $29.5 million Follow-On (February 2017)
  • CymaBay Therapeutics, Inc. in its $10.0 million Follow-On (February 2017)
  • Rigel Pharmaceuticals, Inc. in its $46.0 million Follow-On (January 2017)
  • Mirati Therapeutics, Inc. in its $68.7 million Follow-On (January 2017)
  • Arena Pharmaceuticals Inc. in its $50.0 million Follow-On (January 2017)
  • Aurinia Pharmaceuticals Inc. in its $28.8 million Follow-On (December 2016)
  • Clearside Biomedical, Inc. in its $41.4 million Follow-On (December 2016)
  • Xencor in its $126.5 million Follow-On (November 2016)
  • TRACON Pharmaceuticals, Inc. in its $17.4 million Follow-On (November 2016)
  • Aclaris Therapeutics, Inc. in its $91.0 million Follow-On (November 2016)
  • AmpliPhi Biosciences Corporation in its $4.0 million Follow-On (November 2016)
  • Underwriters in Invitae Corporation $43.9 million Follow-On (November 2016)
  • Flexion Therapeutics in its $64.8 million Follow-On (November 2016)
  • Underwriters in HealthEquity, Inc. $89.6 million Follow-On (October 2016)
  • Sunesis Pharmaceuticals, Inc. $19.0 million Follow-On (October 2016)
  • Underwriters in Ascendis Pharma Inc. $136.4 million Follow-On (October 2016)
  • Underwriters in Nektar Therapeutics in $201.8 million Follow-On (October 2016)
  • Biocept Inc. in its $10.0 million Follow-On (October 2016)
  • Cidara Therapeutics, Inc. in its $25.0 million Follow-On (October 2016)
  • Versartis, Inc. in its $63.4 million Follow-On (September 2016)
  • Enphase Energy, Inc. in its $15.6 million Follow-On (September 2016)
  • Aquinox Pharmaceuticals Inc. in its $65.5 million Follow-On (September 2016)
  • Immune Design Corp. in its $32.7 million Follow-On (September 2016)
  • Underwriters in Xenon Pharmaceuticals Inc. $30.0 million Follow-On (September 2016)
  • AveXis Inc. in its $168.8 million Follow-On (September 2016)
  • Sophiris Bio in its $29.9 million Follow-On (August 2016)
  • Eiger BioPharmaceuticals in its $20 million Follow-On (August 2016)
  • Underwriters in Recro Pharma $14.9 million Follow-On (August 2016)
  • Immunocellular Therapeutics in its $7.5 million Follow-On (August 2016)
  • Acadia Pharmaceuticals Inc. in its $200.0 million Follow-On (August 2016)
  • BioMarin Pharmaceutical Inc. in its $720.0 million Follow-On (August 2016)
  • Paratek Pharmaceuticals, Inc. in its $55.3 million Follow-On (June 2016)
  • Scynexis Inc. in its $22.5 million Follow-On (June 2016)
  • GlycoMimetics, Inc. in its $20.1 million Follow-On (June 2016)
  • Minerva Neurosciences, Inc. in its $57.5 million Follow-On (June 2016)
  • Underwriters in Dermira Inc. $144.9 million Follow-On (June 2016)
  • Flexion Therapeutics, Inc. in its $77.0 million Follow-On (June 2016)
  • AmpliPhi Biosciences Corporation in its $5.0 million Follow-On (May 2016)
  • Sophiris Bio, Inc. in its $5.0 million Follow-On (May 2016)
  • Biocept Inc. in its $5.0 million Follow-On (April 2016)
  • Underwriters in Ignyta, Inc. $57.5 million Follow-On (April 2016)
  • Underwriters in Durect Corporation $17.2 million Follow-On (April 2016)
  • Alder Biopharmaceuticals, Inc. in its $143.8 million Follow-On (April 2016)
  • Underwriters in Vitae Pharmaceuticals, Inc. $40.0 million Follow-On (March 2016)
  • Underwriters in Energy Fuels Inc. $12.1 million Follow-On (March 2016)
  • Adamas Pharmaceuticals in its $61.8 million Follow-On (January 2016)
  • Underwriters in Prothena Corporation plc $119.3 million Follow-On (January 2016)
  • Underwriters in Epizyme, Inc. $138.0 million Follow-On (January 2016)
  • Underwriters in Otonomy, Inc. $115.0 million Follow-On (January 2016)
  • Acadia Pharmaceuticals in its $300.0 million Follow-On (January 2016)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.